Search Results Search Sort by RelevanceMost Recent Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Viewpoint Nov 2005 Steroid Hysteria: Unpacking the Claims Norman Fost, MD, MPH A physician argues in favor of the use of performance-enhancing substances by adult participants in sports. Virtual Mentor. 2005;7(11):767-769. doi: 10.1001/virtualmentor.2005.7.11.oped2-0511. Viewpoint Nov 2005 Medical Ethics and Performance-Enhancing Drugs Carlos R. Hamilton, MD A physician's role in controlling the abuse of performance-enhancing drugs includes educating patients about the harms associated with these drugs and encouraging them to adopt safe and appropriate training programs. Virtual Mentor. 2005;7(11):764-766. doi: 10.1001/virtualmentor.2005.7.11.oped1-0511. Policy Forum Jun 2004 Scope of Practice, Twenty-First Century Grant La Farge, MD Many nonphysician health care practitioners are looking to expand their scope of practice. Virtual Mentor. 2004;6(6):277-278. doi: 10.1001/virtualmentor.2004.6.6.pfor1-0406. Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408. In the Literature Aug 2004 Ethical Issues in the Application and Prescription of CNS Interventions Abraham P. Schwab, PhD A neuroscientist and a sociologist discuss the ethical concerns with common neurological medicines that are used to enhance or change behavior. Virtual Mentor. 2004;6(8):347-349. doi: 10.1001/virtualmentor.2004.6.8.jdsc1-0408. Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520. Health Law Jul 2024 What Should the US Learn From New York’s and Portugal’s Approaches to the Opioid Crisis? Maura McGinnity Some US localities are trying interventions modeled on international approaches to decriminalization. AMA J Ethics. 2024;26(7):E546-550. doi: 10.1001/amajethics.2024.546. Pagination First page « First Previous page ‹ Previous … Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Next page Next › Last page Last »
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Viewpoint Nov 2005 Steroid Hysteria: Unpacking the Claims Norman Fost, MD, MPH A physician argues in favor of the use of performance-enhancing substances by adult participants in sports. Virtual Mentor. 2005;7(11):767-769. doi: 10.1001/virtualmentor.2005.7.11.oped2-0511.
Viewpoint Nov 2005 Medical Ethics and Performance-Enhancing Drugs Carlos R. Hamilton, MD A physician's role in controlling the abuse of performance-enhancing drugs includes educating patients about the harms associated with these drugs and encouraging them to adopt safe and appropriate training programs. Virtual Mentor. 2005;7(11):764-766. doi: 10.1001/virtualmentor.2005.7.11.oped1-0511.
Policy Forum Jun 2004 Scope of Practice, Twenty-First Century Grant La Farge, MD Many nonphysician health care practitioners are looking to expand their scope of practice. Virtual Mentor. 2004;6(6):277-278. doi: 10.1001/virtualmentor.2004.6.6.pfor1-0406.
Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408.
In the Literature Aug 2004 Ethical Issues in the Application and Prescription of CNS Interventions Abraham P. Schwab, PhD A neuroscientist and a sociologist discuss the ethical concerns with common neurological medicines that are used to enhance or change behavior. Virtual Mentor. 2004;6(8):347-349. doi: 10.1001/virtualmentor.2004.6.8.jdsc1-0408.
Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520.
Health Law Jul 2024 What Should the US Learn From New York’s and Portugal’s Approaches to the Opioid Crisis? Maura McGinnity Some US localities are trying interventions modeled on international approaches to decriminalization. AMA J Ethics. 2024;26(7):E546-550. doi: 10.1001/amajethics.2024.546.